Can adding immunotherapy to standard drugs fight resistant breast cancer?
NCT ID NCT03147287
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests three drug combinations—fulvestrant alone, fulvestrant plus palbociclib, and fulvestrant plus palbociclib plus avelumab—in 220 people with ER+/HER2- metastatic breast cancer that has progressed after prior CDK inhibitor therapy. The goal is to see which combination delays cancer growth best. Participants are randomly assigned to one of the three groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Palbociclib (Ibrance), Fulvestrant (Faslodex), Avelumab (Bavencio)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced breast cancer whose disease has progressed after initial therapy.
- What could go wrong
- This is a mid-stage trial with only 220 participants, so results may not apply to everyone. The drugs can cause side effects like low blood counts, fatigue, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aurora Cancer Care
Milwaukee, Wisconsin, 53215, United States
-
Baylor University
Houston, Texas, 77030, United States
-
Boston Medical Center
Boston, Massachusetts, 02188, United States
-
DF/BWCC at Milford Regional Medical Center
Milford, Massachusetts, 01757, United States
-
DF/BWCC in clinical affiliation with South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber at St. Elizabeth's Medical Center
Brighton, Massachusetts, 02135, United States
-
Dana-Farber/New Hampshire Oncology-Hematology
Londonderry, New Hampshire, 03053, United States
-
Eastern Maine Medical Center
Bangor, Maine, 04401, United States
-
Emory University - Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
The University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
The University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
The University of Kansas Cancer Center - North
Kansas City, Kansas, 64154, United States
-
The University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, 66210, United States
-
University of Louisville
Louisville, Kentucky, 40202, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Washington University
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a Four-Drug cocktail tame a tough breast cancer?
- Can a new drug outsmart resistant breast cancer?